Technology | Left Atrial Appendage (LAA) Occluders | April 29, 2016

AtriCure Receives FDA Clearance for New AtriClip Device

AtriClip PRO2 LAA Exclusion System features a streamlined hoopless end effector

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance

April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.

The new system features an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers and a hoopless end effector. The ambidextrous locking and trigger-style clip closing mechanism allows the operator to maintain focus on the LAA while maneuvering the device. The handle-based active articulation levers allow the operator to steer the end effector without removing the device. The hoopless end effector enhances anatomical visualization, and simplifies removal of the applier after deployment of the clip.

“The AtriClip PRO2 system provides easier placement of the proven AtriClip LAA occlusion technology,” said J. Michael Smith, M.D. at TriHealth Heart Institute in Cincinnati. “The new deployment system facilitates less invasive treatment of the LAA, including right chest approaches in conjunction with valve replacement and cardiac ablation procedures.”

For more information: www.atricure.com

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init